pharma news today obesity drugs glp-1 september 2025 Anti-Obesity Drug Market Outlook 2025–2032: Strong CAGR of 18.01% with USD 82.55 Billion Valuation Weight-loss market to see 16

Sergey Terushkin, MD, FACS is a fellowship-trained bariatric surgeon with experience in bariatric surgery, obesity medicine, medical weight loss, and long-term weight management

In fact, studies have revealed an inverse correlation between DPP-4 activity levels and BMD, suggesting a likely role of DPP-4 in bone homeostasis [5,6,7,8, 10]

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Using this scenario, if a weight loss drug helps you to keep your weight off then you may continue using it even as your weight normalizes as long as you qualified to take it in the first place

Novo Nordisk has defended the drugs safety and efficacy and stands by how they have shared warnings and side effects

Studying pancreatic risks caused by incretin-based therapies: Is it a game